Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Clin Cancer Res. 2017 Aug 8;23(21):6541–6554. doi: 10.1158/1078-0432.CCR-17-0947

Figure 6. The combination of vorinostat and AZD1775 inhibits tumor growth in an orthotopic mouse model of oral cancer and prolongs animal survival.

Figure 6

A, tumor growth curves in orthotopic mouse model oral tongues bearing PC13-G245D cells with high-risk mutant TP53 following treatment with either vorinostat (65 mg/kg), AZD1775 alone (45 mg/kg) or in combination. B, Kaplan-Meier analysis for overall survival. C, phospho-CDK1 (tyr15) expression levels in the orthotopic tongue tumors. D, Quantification of phospho-CDK1 levels shown in Figure 5C. E and F, CD31 immunohistochemistry and quantification of microvessel density. G and H, TUNEL-positive apoptotic cells in tissue sections obtained from tumors of mice treated with drugs as indicated.